Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Sirolimus for Aggressive Retinal Astrocytic Hamartoma
NCT04707209Completed
- Sponsor
- SickKids
- Start
- Nov 2020
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sirolimus in Retinal astrocytic hamartoma (RAH), sponsored by SickKids. Primary endpoints: Size of Retinal Astrocytic Hamartomas at 21 months, Amount of retinal exudate at 21 months and 1 more. Started Nov 2020; status: completed.
02
Drugs
sirolimus
03
Conditions
Retinal astrocytic hamartoma (RAH)
Beyond the preview
Go deeper on NCT04707209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707209.